90Y‐ibritumomab tiuxetan in patients with extra‐nodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma) — The Zeno Study
Open Access
- 13 January 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 189 (1), e6-e9
- https://doi.org/10.1111/bjh.16404
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Epidemiology and environmental aspects of marginal zone lymphomasBest Practice & Research Clinical Haematology, 2017
- Phase II study of90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphomaLeukemia & Lymphoma, 2014
- 90Y‐ibritumomab tiuxetan radiotherapy as first‐line therapy for early stage low‐grade B‐cell lymphomas, including bulky diseaseBritish Journal of Haematology, 2014
- Efficacy of90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphomaHematological Oncology, 2013
- Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphomaLeukemia & Lymphoma, 2006
- Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell LymphomaClinical Lymphoma, 2004